Image Place holder

Aleksandr Lazaryan, MD, MPH, PhD

 
Specialty: Blood and Marrow Transplant and Cellular Immunotherapy
Sub Specialty: Medical Oncology, Hematology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Overview

Cancer Focus: Hodgkin Lymphoma, Non-Hodgkin Lymphoma


Education & Training

Board Certification:

  • Internal Medicine - Medical Oncology
  • Internal Medicine - Hematology
Participating Trials

CLINICAL TRIAL 19877
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Varlilumab ()
Open

CLINICAL TRIAL 20397
A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Condition: Immunotherapy
Intervention: Itacitinib ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Bejanyan N, Rogosheske J, Cao Q, Lazaryan A, Holton S, Ustun C, Jacobson P, MacMillan M, Weisdorf DJ, Wagner J, Arora M, Brunstein CG. Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. Eur J Haematol. 2021 Feb.106(2):205-212. Pubmedid: 33084139. Pmcid: PMC8711731.
  • Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Tr. 2019 Sep.25(9):1875-1883. Pubmedid: 31085303. Pmcid: PMC7071947.
  • Holtan SG, Zhang L, DeFor TE, Bejanyan N, Arora M, Rashidi A, Lazaryan A, Kotiso F, Blazar BR, Wagner JE, Brunstein CG, MacMillan ML, Weisdorf DJ. Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation. Biol Blood Marrow Tr. 2019 Sep.25(9):1884-1889. Pubmedid: 31128328. Pmcid: PMC6755055.
  • Goyal-O'Leary A, Hordinsky M, Lazaryan A. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin. Dermatol Ther. 2019 Mar.32(2):e12835. Pubmedid: 30659762.
  • Goyal A, O'Leary D, Goyal K, Rubin N, Bohjanen K, Hordinsky M, Chen ST, Pongas G, Duncan LM, Lazaryan A. Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis. J Am Acad Dermatol. 2019 Jul.83(2):404-411. Pubmedid: 31374302. Pmcid: PMC7021276.
  • Warlick ED, DeFor TE, Bejanyan N, Holtan S, MacMillan M, Blazar BR, Dusenbery K, Arora M, Bachanova V, Cooley S, Lazaryan A, McGlave P, Miller JS, Rashidi A, Slungaard A, Vercellotti G, Ustun C, Brunsein C, Weisdorf D. Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. Biol Blood Marrow Tr. 2019 Jan.25(1):56-62. Pubmedid: 30077015. Pmcid: PMC6310652.
  • Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 Jan.12(1):6. Pubmedid: 30630534. Pmcid: PMC6329157.
  • Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Ustun C, Warlick ED, Arora M, Wagner JE, Weisdorf DJ. Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. Blood Adv. 2019 Feb.3(3):230-236. Pubmedid: 30674457. Pmcid: PMC6373743.
  • Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Tr. 2019 Dec.25(12):2305-2321. Pubmedid: 31446199.
  • Spellecy R, Tarima S, Denzen E, Moore H, Abhyankar S, Dawson P, Foley A, Gersten I, Horwitz M, Idossa L, Joffe S, Kamani N, King R, Lazaryan A, Morris L, Horowitz MM, Majhail NS. Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. Biol Blood Marrow Tr. 2018 Oct.24(10):2145-2151. Pubmedid: 29679770. Pmcid: PMC6193865.
  • Khouri J, Rybicki L, Majhail N, Kalaycio M, Copelan E, Pohlman B, Hill B, Dean R, Lazaryan A, Hamilton B, Andresen S, Sobecks R, Bolwell B, Liu H. Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. J Clin Apher. 2018 Jun.33(3):303-309. Pubmedid: 29134688.
  • Keklik F, Alrawi EB, Cao Q, Bejanyan N, Rashidi A, Lazaryan A, Arndt P, Dincer EH, Bachanova V, Warlick ED, MacMillan ML, Arora M, Miller J, Brunstein CG, Weisdorf DJ, Ustun C. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics. Haematologica. 2018 Dec.103(12):2109-2115. Pubmedid: 30076172. Pmcid: PMC6269296.
  • Santiago V, Lazaryan A, McClune B, McKenna RW, Courville EL. Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome. Leuk Lymphoma. 2018 Apr.59(4):958-966. Pubmedid: 28728454. Pmcid: PMC5776059.
  • Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, Mehta RS, Warlick E, Cooley SA, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018 Apr.2(8):909-922. Pubmedid: 29678809. Pmcid: PMC5916001.
  • Belete H, Burns LJ, Shanley R, Nayar M, McClune B, Lazaryan A, Bachanova V, Bejanyan N, Ustun C, Brunstein C, Weisdorf DJ, Arora M. Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. Am J Hematol. 2017 Sep.92(9):E529-E533. Pubmedid: 28612451. Pmcid: PMC5733686.
  • Wilke C, Cao Q, Dusenbery KE, Bachanova V, Lazaryan A, Lee CK, Yuan J. Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2017 Sep.99(1):94-102. Pubmedid: 28816170. Pmcid: PMC5744586.
  • He F, Cao Q, Lazaryan A, Brunstein C, Holtan S, Warlick E, Ustun C, McClune B, Arora M, Rashidi A, Eckfeldt C, Weisdorf DJ, Bejanyan N. Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. Biol Blood Marrow Tr. 2017 Sep.23(9):1485-1490. Pubmedid: 28522345. Pmcid: PMC5586072.
  • Lazaryan A, Arora M. Evolving concepts in prognostic scoring of chronic GvHD. Bone Marrow Transplant. 2017 Oct.52(10):1361-1366. Pubmedid: 28346419.
  • Hegerova L, Cao Q, Lazaryan A, McClune BL, Weisdorf DJ, Brunstein CG, Bachanova V. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant. 2017 May.52(5):697-703. Pubmedid: 28134921. Pmcid: PMC5415418.
  • Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant. 2017 Mar.52(3):400-408. Pubmedid: 27941764. Pmcid: PMC5332289.
  • Fair C, Shanley R, Rogosheske J, Lazaryan A, McClune B, Brunstein CG, Bachanova V. BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications. Bone Marrow Transplant. 2017 Mar.52(3):491-493. Pubmedid: 28067889. Pmcid: PMC5332312.
  • Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SG, Schultz K, Müller CR, Fernandez-Viña MA, Verneris MR, Horowitz MM, Arora M, Weisdorf DJ, Lee SJ. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica. 2016 Oct.101(10):1267-1274. Pubmedid: 27247320. Pmcid: PMC5046657.
  • Courville EL, Yohe S, Chou D, Nardi V, Lazaryan A, Thakral B, Nelson AC, Ferry JA, Sohani AR. EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations. Mod Pathol. 2016 Oct.29(10):1200-1211. Pubmedid: 27443517.
  • Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. Biol Blood Marrow Tr. 2016 Nov.22(11):2025-2030. Pubmedid: 27519278. Pmcid: PMC5067231.
  • Omer AK, Weisdorf DJ, Lazaryan A, Shanley R, Blazar BR, MacMillan ML, Brunstein C, Bejanyan N, Arora M. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Tr. 2016 May.22(5):879-883. Pubmedid: 26743342. Pmcid: PMC4922492.
  • Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. Haematologica. 2016 Jun.101(6):764-772. Pubmedid: 27036159. Pmcid: PMC5013959.
  • Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, Holtan S, Blazar BR, Wagner JE, Arora M. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors. Biol Blood Marrow Tr. 2016 Jan.22(1):134-140. Pubmedid: 26365153. Pmcid: PMC4787268.
  • Rouphael B, Lankireddy S, Lazaryan A, Kukla A, Ibrahim HN, Matas AJ, Issa N. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder. Clin Transplant. 2016 Jan.30(1):60-65. Pubmedid: 26497471.
  • Lazaryan A. Expecting a Miracle Harvest after Miracle Growth: Controversies of Granulocyte Colony-Stimulating Factor-Mobilized Matched Sibling Donor Transplantation. Biol Blood Marrow Tr. 2016 Aug.22(8):1343-1345. Pubmedid: 27321366.
  • Bejanyan N, Rogosheske J, DeFor T, Lazaryan A, Esbaum K, Holtan S, Arora M, MacMillan ML, Weisdorf D, Jacobson P, Wagner J, Brunstein CG. Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. Biol Blood Marrow Tr. 2015 May.21(5):926-933. Pubmedid: 25655791. Pmcid: PMC4768800.
  • Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res. 2015 Mar.21(6):1267-1272. Pubmedid: 25770294. Pmcid: PMC4360883.
  • Bachanova V, Cao Q, Ustun C, Kendi AT, Froelich J, Lazaryan A, Burns LJ. Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT. Bone Marrow Transplant. 2015 Jan.50(1):142-144. Pubmedid: 25265460. Pmcid: PMC4753777.
  • Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, Blazar BR, MacMillan ML, Weisdorf DJ. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015 Feb.125(8):1333-1338. Pubmedid: 25593335. Pmcid: PMC4335084.
  • Lazaryan A, Hussein MA, Reu FJ, Faiman B, Habecker B, Ann Karam M, Reed J, Hamilton K, Waksman J, Bruening K, Srkalovic G, Andresen S, Kalaycio M, Sweetenham JW, Sobecks R, Dean R, Knight R, Zeldis JB, Baz R. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. Am J Hematol. 2014 Apr.89(4):349-354. Pubmedid: 24273135.
  • Bejanyan N, Bolwell BJ, Lazaryan A, Rybicki L, Tench S, Duong H, Andresen S, Sobecks R, Dean R, Pohlman B, Kalaycio M, Copelan EA. Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT). Biol Blood Marrow Tr. 2012 Jun.18(6):874-880. Pubmedid: 22040844.
  • Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. Eur J Surg Oncol. 2011 Sep.37(9):791-797. Pubmedid: 21741199.
  • Avalos BR, Lazaryan A, Copelan EA. Can G-CSF cause leukemia in hematopoietic stem cell donors?. Biol Blood Marrow Tr. 2011 Dec.17(12):1739-1746. Pubmedid: 21745453.
  • Lazaryan A, Song W, Lobashevsky E, Tang J, Shrestha S, Zhang K, McNicholl JM, Gardner LI, Wilson CM, Klein RS, Rompalo A, Mayer K, Sobel J, Kaslow RA. The influence of human leukocyte antigen class I alleles and their population frequencies on human immunodeficiency virus type 1 control among African Americans. Hum Immunol. 2011 Apr.72(4):312-318. Pubmedid: 21262311. Pmcid: PMC3778654.
  • Lazaryan A, Song W, Lobashevsky E, Tang J, Shrestha S, Zhang K, Gardner LI, McNicholl JM, Wilson CM, Klein RS, Rompalo A, Mayer K, Sobel J, Kaslow RA. Human leukocyte antigen class I supertypes and HIV-1 control in African Americans. J Virol. 2010 Mar.84(5):2610-2617. Pubmedid: 20032191. Pmcid: PMC2820922.
  • Kim R, Tsao R, Tan A, Byrne M, Almhanna K, Lazaryan A, Elson P, Pelley RJ. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg. 2010 Jul.14(7):1159-1169. Pubmedid: 20446118.
  • Bejanyan N, Fu AZ, Lazaryan A, Fu R, Kalaycio M, Advani A, Sobecks R, Copelan E, Maciejewski JP, Sekeres MA. Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia. Cancer. 2010 Aug.116(15):3614-3620. Pubmedid: 20564070.
  • Lazaryan A, Lobashevsky E, Mulenga J, Karita E, Allen S, Tang J, Kaslow RA. Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native Africans. J Virol. 2006 Jun.80(12):6056-6060. Pubmedid: 16731944. Pmcid: PMC1472610.
  • Shao W, Lazaryan A, Dorak MT, Penman-Aguilar A, Wilson CM, Margolick JB, Goedert JJ, Prins M, Tang J, Kaslow RA. Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progression. Aids. 2006 Aug.20(12):1583-1590. Pubmedid: 16868438.

Grants

Title: Promoting an Effective Immune Response in Lymphoma
Sponsor: US Army
PI: Lazaryan, A.

Patient Comments
Overall Satisfaction
0

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments